[Spironolactone-thiazides-reserpine. Antihypertensive effect in essential arterial hypertension].
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012110:Reserpine / Q000008:administration & dosage / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D012110:Reserpine
Espironolactona-tiazida-reserpina. Efecto antihipertensivo en hipertensión arterial esencial